M E Williams

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint The next generation of diabetic nephropathy therapies: an update
    Mark E Williams
    Joslin Diabetes Center, Boston, MA 02215, USA
    Adv Chronic Kidney Dis 12:212-22. 2005
  2. doi request reprint Diabetic CKD/ESRD 2010: a progress report?
    Mark E Williams
    Department of Medicine, Harvard Medical School, Joslin Diabetes Center and Beth Israel Deaconess Medical Center, Boston, MA, USA
    Semin Dial 23:129-33. 2010
  3. doi request reprint Chronic kidney disease/bone and mineral metabolism: the imperfect storm
    Mark E Williams
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Semin Nephrol 29:97-104. 2009
  4. doi request reprint Glycemic management in ESRD and earlier stages of CKD
    Mark E Williams
    Renal Division, Joslin Diabetes Center, Boston, MA Electronic address
    Am J Kidney Dis 63:S22-38. 2014
  5. doi request reprint Diabetic kidney disease in elderly individuals
    Mark E Williams
    Renal Unit, Joslin Diabetes Center, Boston, MA 02215, USA
    Med Clin North Am 97:75-89. 2013
  6. ncbi request reprint The ESRD uninsured matter
    Mark E Williams
    Joslin Diabetes Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Adv Chronic Kidney Dis 14:67-74. 2007
  7. ncbi request reprint Coronary revascularization in diabetic chronic kidney disease/end-stage renal disease: a nephrologist's perspective
    Mark E Williams
    Renal Unit, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA
    Clin J Am Soc Nephrol 1:209-20. 2006
  8. ncbi request reprint Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy
    Mark E Williams
    Harvard Medical School, Joslin Diabetes Center, Boston, MA 02215, USA
    Am J Nephrol 27:605-14. 2007
  9. doi request reprint Extremes of glycemic control (HbA1c) increase hospitalization risk in diabetic hemodialysis patients in the USA
    M E Williams
    Renal Unit, Joslin Diabetes Center, Boston, MA, USA
    Am J Nephrol 29:54-61. 2009
  10. ncbi request reprint Management of diabetes in dialysis patients
    Mark E Williams
    Joslin Diabetes Center, One Joslin Place, Boston, MA 02215, USA
    Curr Diab Rep 9:466-72. 2009

Detail Information

Publications27

  1. ncbi request reprint The next generation of diabetic nephropathy therapies: an update
    Mark E Williams
    Joslin Diabetes Center, Boston, MA 02215, USA
    Adv Chronic Kidney Dis 12:212-22. 2005
    ..To determine whether clinical outcomes (mortality, renal, and cardiovascular events) are improved beyond the current standard of care, phase III trials are planned...
  2. doi request reprint Diabetic CKD/ESRD 2010: a progress report?
    Mark E Williams
    Department of Medicine, Harvard Medical School, Joslin Diabetes Center and Beth Israel Deaconess Medical Center, Boston, MA, USA
    Semin Dial 23:129-33. 2010
    ....
  3. doi request reprint Chronic kidney disease/bone and mineral metabolism: the imperfect storm
    Mark E Williams
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Semin Nephrol 29:97-104. 2009
    ..Current therapies directed at correcting the primary abnormalities (ie, improve conditions to an imperfect storm) and minimizing the consequences of CKD/BMD are discussed...
  4. doi request reprint Glycemic management in ESRD and earlier stages of CKD
    Mark E Williams
    Renal Division, Joslin Diabetes Center, Boston, MA Electronic address
    Am J Kidney Dis 63:S22-38. 2014
    ..The article provides information to help clinicians in decision making in order to provide individualized glycemic goals and appropriate therapy for patients with ESRD or earlier stages of CKD. ..
  5. doi request reprint Diabetic kidney disease in elderly individuals
    Mark E Williams
    Renal Unit, Joslin Diabetes Center, Boston, MA 02215, USA
    Med Clin North Am 97:75-89. 2013
    ..There is a growing need for the development of clinical guidelines to retool CKD management in the elderly diabetic population using both current and emerging therapies...
  6. ncbi request reprint The ESRD uninsured matter
    Mark E Williams
    Joslin Diabetes Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Adv Chronic Kidney Dis 14:67-74. 2007
    ..It also presents a health-care reform measure in Massachusetts designed to provide affordable insurance to those without coverage...
  7. ncbi request reprint Coronary revascularization in diabetic chronic kidney disease/end-stage renal disease: a nephrologist's perspective
    Mark E Williams
    Renal Unit, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA
    Clin J Am Soc Nephrol 1:209-20. 2006
  8. ncbi request reprint Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy
    Mark E Williams
    Harvard Medical School, Joslin Diabetes Center, Boston, MA 02215, USA
    Am J Nephrol 27:605-14. 2007
    ..We report the results of safety/tolerability studies in patients with overt nephropathy and type 1/type 2 diabetes treated with pyridoxamine, a broad inhibitor of advanced glycation...
  9. doi request reprint Extremes of glycemic control (HbA1c) increase hospitalization risk in diabetic hemodialysis patients in the USA
    M E Williams
    Renal Unit, Joslin Diabetes Center, Boston, MA, USA
    Am J Nephrol 29:54-61. 2009
    ....
  10. ncbi request reprint Management of diabetes in dialysis patients
    Mark E Williams
    Joslin Diabetes Center, One Joslin Place, Boston, MA 02215, USA
    Curr Diab Rep 9:466-72. 2009
    ..Recent studies on HbA(1c) and clinical outcomes in this population present complementary results on the role of glycemic control in patients with DM with ESRD...
  11. pmc Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses
    Mark E Williams
    Renal Unit, Joslin Diabetes Center, Boston, MA 02215, USA
    Clin J Am Soc Nephrol 5:1595-601. 2010
    ..Recent large observational studies with differing methodologies reached somewhat contrasting conclusions regarding the association of hemoglobin A1c with survival in diabetic chronic hemodialysis patients...
  12. doi request reprint The goal of blood pressure control for prevention of early diabetic microvascular complications
    Mark E Williams
    Renal Unit, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA
    Curr Diab Rep 11:323-9. 2011
    ..This review discusses the relationship between hypertension, diabetes, and kidney disease, the rationale for primary prevention, and the data that led to that conclusion...
  13. ncbi request reprint New potential agents in treating diabetic kidney disease: the fourth act
    Mark E Williams
    Renal Unit, the Joslin Diabetes Center, Boston, Massachusetts 02215, USA
    Drugs 66:2287-98. 2006
    ..Phase III evaluation of pyridoxamine has not begun. These three classes of potential therapies, if successfully developed, will confirm that diabetic kidney disease has entered the era of biochemical treatments...
  14. ncbi request reprint Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival
    M E Williams
    Renal Unit, Joslin Diabetes Center, One Joslin Place, Boston, Massachusetts, USA
    Kidney Int 70:1503-9. 2006
    ..More studies are needed to refine recommendations for the role of HgbA1c and glycemic control in this patient population...
  15. ncbi request reprint Internet organ solicitation, explained
    Mark E Williams
    Joslin Diabetes Center, Harvard Medical School, Boston, MA 02215, USA
    Adv Chronic Kidney Dis 13:70-5. 2006
    ..However, a lack of rules and regulations regarding internet solicitation exists. Several pragmatic steps are proposed...
  16. ncbi request reprint New therapies for advanced glycation end product nephrotoxicity: current challenges
    Mark E Williams
    Joslin Diabetes Center and Harvard Medical School, Boston, MA, USA
    Am J Kidney Dis 41:S42-7. 2003
    ..However, the structural diversity of AGE chemistry has created new challenges in the search for AGE-based inhibition therapies...
  17. ncbi request reprint Promise or peril? Impact of the Medicare drug benefit on the ESRD population
    Mark E Williams
    Beth Israel Deconess Medical Centerand Harvard Medical School, Boston, MA, USA
    Adv Chronic Kidney Dis 11:228-33. 2004
  18. ncbi request reprint Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease
    Mark E Williams
    Joslin Diabetes Center, Harvard Medical School, 1 Joslin Place, Boston, MA 02215, USA
    Curr Diab Rep 4:441-6. 2004
    ..This article reports progression through human studies of the few AGE inhibitors that have reached clinical development, including pimagedine, pyridoxamine, and alagebrium...
  19. ncbi request reprint The involuntarily discharged dialysis patient: conflict (of interest) with providers
    Mark E Williams
    Division of Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Adv Chronic Kidney Dis 12:107-12. 2005
  20. ncbi request reprint Diabetic nephropathy: the proteinuria hypothesis
    Mark E Williams
    Joslin Diabetes Center, Harvard Medical School, Boston, Mass, USA
    Am J Nephrol 25:77-94. 2005
    ....
  21. ncbi request reprint Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy
    W Kline Bolton
    Department of Medicine, University of Virginia Health System, Charlottesville, Va 2908 0133, USA
    Am J Nephrol 24:32-40. 2004
    ..This study was undertaken to determine if pimagedine ameliorates nephropathy in type 1 (insulin-dependent) diabetes mellitus...
  22. ncbi request reprint Renal failure resulting from infiltration by inflammatory myofibroblastic tumor responsive to corticosteroid therapy
    M E Williams
    Renal Unit, Joslin Diabetes Center, 1 Joslin Pl, Boston, MA 02215, USA
    Am J Kidney Dis 31:E5. 1998
    ..Renal failure responded favorably over weeks to corticosteroid therapy (serum creatinine level, 2.8 mg/dL) with a marked reduction in bilateral renal enlargement by CT scan...
  23. ncbi request reprint Medicare medical nutrition therapy: legislative process and product
    Mark E Williams
    Harvard Medical School, Cambridge, MA, USA
    J Ren Nutr 12:1-7. 2002
    ..The definition of MNT and the scientific evidence supporting it are presented. Evidence-based nutrition now enters a new phase of implementation and additional analysis...
  24. doi request reprint Geriatric nephrology: responding to a growing challenge
    Mitchell Rosner
    Division of Nephrology, University of Virginia Health System, Charlottesville, VA 22908, USA
    Clin J Am Soc Nephrol 5:936-42. 2010
    ....
  25. doi request reprint Use of circulating antiangiogenic factors to differentiate other hypertensive disorders from preeclampsia in a pregnant woman on dialysis
    Hui Yi Shan
    Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Am J Kidney Dis 51:1029-32. 2008
    ..Additional studies in this particular group of patients are required...
  26. ncbi request reprint Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4
    Jack W Coburn
    West Los Angeles Veterans Affairs Healthcare Center, Los Angeles, CA 90073, USA
    Am J Kidney Dis 43:877-90. 2004
    ..We evaluated doxercalciferol (1alpha-hydroxyvitamin D2) as an alternative therapy in a randomized, double-blinded, placebo-controlled, multicenter trial...
  27. ncbi request reprint Caring for our future selves
    Mark E Williams
    Am J Med 117:537-40. 2004